An exploratory, randomized, double blind, placebo controlled, parallel groups Phase II clinical trial to evaluate the efficacy and safety of E-52862 (400 mg) by oral route, in patients with post-surgical neuropathic pain.

Trial Profile

An exploratory, randomized, double blind, placebo controlled, parallel groups Phase II clinical trial to evaluate the efficacy and safety of E-52862 (400 mg) by oral route, in patients with post-surgical neuropathic pain.

Completed
Phase of Trial: Phase II

Latest Information Update: 30 Sep 2016

At a glance

  • Drugs E 52862 (Primary)
  • Indications Neuropathic pain; Postoperative pain
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Esteve
  • Most Recent Events

    • 30 Sep 2016 Primary endpoint (Time specific change from baseline to day 28 in mean pain intensity in the previous 7 days interval measured by a Numerical Pain Rating Scale (NPRS) included in a patient diary) has been met, according to the results presented at the 16th World Congress on Pain.
    • 30 Sep 2016 Results presented at the 16th World Congress on Pain
    • 24 Jan 2015 Status changed from recruiting to completed as reported by European Clinical Trials Database record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top